Back to Search
Start Over
13883 Maintenance of response through 136 weeks of long-term continuous risankizumab treatment: An analysis of patients from UltIMMa-1 and UltIMMa-2
- Source :
- Journal of the American Academy of Dermatology. 83:AB14
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
Details
- ISSN :
- 01909622
- Volume :
- 83
- Database :
- OpenAIRE
- Journal :
- Journal of the American Academy of Dermatology
- Accession number :
- edsair.doi...........21191baa7a7f60f6bb8ea7e9d274b031
- Full Text :
- https://doi.org/10.1016/j.jaad.2020.06.143